UCBJF:OTCMKTS
UCB SA
240,24 US$
arrow_upward
+1,82%(+4,30) 1D
15 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për UCBJF...
Hap
240,24 US$
I lartë
240,24 US$
I ulët
240,24 US$
Kapitalizimi i tregut
38,81 mld
Vëllimi mesatar
139,00
Vëllimi
10,00
Maksimumi 52-javor
345,39 US$
Minimumi 52-javor
219,60 US$
Beta
0,58
Aksionet në qarkullim
194,51 mln
Numri i punonjësve
9 mijë
Hap
240,24 US$
I lartë
240,24 US$
I ulët
240,24 US$
Kapitalizimi i tregut
38,81 mld
Vëllimi mesatar
139,00
Vëllimi
10,00
Maksimumi 52-javor
345,39 US$
Minimumi 52-javor
219,60 US$
Beta
0,58
Aksionet në qarkullim
194,51 mln
Numri i punonjësve
9 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
22 orë më parë
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profili
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Rreth UCB SA
Drejtori ekzekutivJean-Christophe Tellier
Punonjësit9 mijë
Themeluar më18 jan 1928
Selia-
Sektori-
Uebsajtiucb.com